PBA
UTHR icon

Paradigm Biocapital Advisors’s United Therapeutics UTHR Stock Holding History

Paradigm Biocapital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-307,314
Closed -$69.4M – 36
2023
Q3 		$69.4M Buy
307,314
+68,926
+29% +$15.9M 4.71% 9
2023
Q2 		$52.6M Buy
238,388
+26,496
+13% +$5.87M 4.07% 10
2023
Q1 		$47.5M Buy
211,892
+63,000
+42% +$15.5M 4.5% 11
2022
Q4 		$41.4M Buy
148,892
+8,331
+6% +$2.1M 4.86% 11
2022
Q3 		$29.4M Sell
140,561
-22,505
-14% -$5.03M 3.92% 11
2022
Q2 		$38.4M Buy
163,066
+87,431
+116% +$17.8M 7.66% 7
2022
Q1 		$13.6M Buy
+75,635
New +$14.4M 3.59% 12

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paradigm Biocapital Advisors's UTHR Position: Q4 2023 in Review

Paradigm Biocapital Advisors sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 307,314 shares — an estimated $69.4M sold.

Paradigm Biocapital Advisors first reported a position in UTHR in Q1 2022 and held it in 7 quarters. The position peaked at $69.4M in Q3 2023. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

  • Paradigm Biocapital Advisors reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 307,314 United Therapeutics shares in Q4 2023, an estimated $69.4M.
  • Paradigm Biocapital Advisors first reported a position in United Therapeutics in Q1 2022 and held it in 7 quarters.
  • Paradigm Biocapital Advisors's United Therapeutics position peaked at $69.4M in Q3 2023.
  • 535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.